Cargando…
Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children, whereas it is less common in adults. Identification of cytogenetic aberrations and a small number of molecular abnormalities are still the most important risk and therapy stratification methods in clinical practice...
Autores principales: | Janic, Dragana, Peric, Jelena, Karan-Djurasevic, Teodora, Kostic, Tatjana, Marjanovic, Irena, Stanic, Bojana, Pejanovic, Nadja, Dokmanovic, Lidija, Lazic, Jelena, Krstovski, Nada, Virijevic, Marijana, Tomin, Dragica, Vidovic, Ana, Suvajdzic-Vukovic, Nada, Pavlovic, Sonja, Tosic, Natasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Medical Biochemists of Serbia, Belgrade
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290126/ https://www.ncbi.nlm.nih.gov/pubmed/32550823 http://dx.doi.org/10.2478/jomb-2019-0017 |
Ejemplares similares
-
Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
por: Virijevic, Marijana, et al.
Publicado: (2016) -
PB1821: THE INFLUENCE OF BCL2, BAX, BAX/BCL2 RATIO AND MDR1 GENE EXPRESSION ON PROGNOSIS OF ADULT DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE
por: Pravdic, Zlatko, et al.
Publicado: (2023) -
The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients
por: Pravdic, Zlatko, et al.
Publicado: (2023) -
Pharmacogenomic Markers of Glucocorticoid Response in The Initial Phase of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2018) -
Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment
por: Kotur, Nikola, et al.
Publicado: (2020)